Statera BioPharma (Statera BioPharma) Capex-to-Revenue : 0.00 (As of Sep. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Statera BioPharma Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Statera BioPharma's Capital Expenditure for the three months ended in Sep. 2022 was $0.00 Mil. Its Revenue for the three months ended in Sep. 2022 was $0.00 Mil.

GuruFocus do not calculate Capex-to-Revenue if the revenue is negative.

Statera BioPharma Capex-to-Revenue Historical Data

The historical data trend for Statera BioPharma's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Statera BioPharma Capex-to-Revenue Chart

Statera BioPharma Annual Data

Trend

Dec19

Dec20

Dec21

Capex-to-Revenue

Statera BioPharma Quarterly Data
	Dec19	Mar20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Capex-to-Revenue	Get a 7-Day Free Trial						-	-	-	-	-

Competitive Comparison of Statera BioPharma's Capex-to-Revenue

For the Biotechnology subindustry, Statera BioPharma's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Statera BioPharma's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Statera BioPharma's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Statera BioPharma's Capex-to-Revenue falls into.

Statera BioPharma Capex-to-Revenue Calculation

Statera BioPharma's Capex-to-Revenue for the fiscal year that ended in Dec. 2021 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- (-0.183)	/	0
	=	N/A

Statera BioPharma's Capex-to-Revenue for the quarter that ended in Sep. 2022 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- (0)	/	0
	=	N/A

Statera BioPharma (OTCPK:STAB) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.

Statera BioPharma Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Statera BioPharma's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Statera BioPharma (Statera BioPharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Statera BioPharma Inc (OTCPK:STAB) » Definitions » Capex-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

4333 Corbett Drive, Suite 1082, Fort Collins, CO, USA, 80525

Website

https://www.staterabiopharma.com

Statera BioPharma Inc is a pre-clinical and clinical biopharmaceutical company developing multiple product candidates to address unmet medical needs for use in diseases involving immune system dysfunction.

Executives

Satishchandran Chandrasekhar	director	167 CARMELA COURT, JUPITER FL 33478
Taunia Markvicka	director, officer: Chief Operating Officer	2537 RESEARCH BOULEVARD, SUITE 201, FORT COLLINS CO 80526
Robert Buckheit	officer: Chief Technology Officer	C/O CYTOCOM INC., 2537 RESEARCH BLVD, SUITE 201, FORT COLLINS CO 80526
Mcavoy Cozette M.	officer: Chief Legal Officer	2537 RESEARCH BOULEVARD, SUITE 201, FORT COLLINS CO 80526
Michael K Handley	director, officer: President and CEO	9965 FEDERAL DRIVE, COLORADO SPRINGS CO 80921
Clifford Selsky	officer: Chief Medical Officer	2537 RESEARCH BOULERVARD, SUITE 201, FORT COLLINS CO 80526
Peter Aronstam	officer: Chief Financial Officer	2537 RESEARCH BLVD, SUITE 201, FORT COLLINS CO 80526
Steve K Barbarick	director	TRACTOR SUPPLY COMPANY, 5401 VIRGINIA WAY, BRENTWOOD TN 37027
Christopher Zosh	officer: Vice President of Finance	C/O CLEVELAND BIOLABS, INC., 73 HIGH STREET, BUFFALO NY 14203
Ivan Fedyunin	director	73 HIGH STREET, BUFFALO NY 14203
John Edward Szydlo	officer: Principal Financial Officer	73 HIGH STREET, BUFFALO NY 14203
Alexander Andryushechkin	director	73 HIGH STREET, BUFFALO NY 14203
Daniil Talyanskiy	director	73 HIGH STREET, BUFFALO NY 14203
Lea Verny	director	73 HIGH STREET, BUFFALO NY 14203
Alexey Nechaev	director	73 HIGH STREET, BUFFALO NY 14203